Cyclo Therapeutics Achieves Landmark Milestone With Completion of Enrollment of Last Patient in Phase 3 Pivotal Transportnpc™ Trial of Niemann-Pick Type C1
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.